Objectives Infliximab, an anti-TNF agent, is used to treat sarcoidosis that does not respond to corticosteroids or second-line agents. The efficacy of other anti-TNF agents, non-TNF biologics and ...

At first glance, some people seem to have recovered from COVID-19. They no longer test positive and can return to work or school.

Restrictive lung disease is often aggravated by comorbidities as previously described and the patients are at risk for severe and recurrent infections. Because of a slower disease progression, ...

A new study links calorie-restrictive diets to higher depressive symptoms, as experts emphasize the role of balanced nutrition and mental health support.

The proposed budget for the Department of Health and Human Services slashes CDC and NIH funding in favor of the new Administration for a Healthy America.

Dr. Suresh Ramalingam discusses how Tagrisso has ushered in a new era of care for patients with advanced EGFR+ non-small cell lung cancer.

TIXiMED Announces Successful Completion of a Phase 1 Study of its Novel Oral Disease-Modifying Type 1 Diabetes Therapy, TIX100 ...

The therapeutic landscape of small cell lung cancer (SCLC) is undergoing a paradigm shift with the emergence of delta-like ligand-3 (DLL3)–directed therapies, particularly tarlatamab, a first-in-class ...

A 46-year-old woman with type 1 myotonic dystrophy (DM1) presented to the emergency department with dyspnea and palpitations. The patient had a history of mild cognitive impairment, muscle weakness, ...

Researchers investigate the cause of lung damage in autoimmune diseases by Jan Grabowski, Zentrum für Experimentelle und Klinische Infektionsforschung ...

Tubbins was born with a restrictive lung disease that impacts her daily life. However, with each challenge comes another opportunity to overcome an obstacle. "I never quit," said Tubbins. "Never ...

French President Emmanuel Macron gives a shout-out to Clair Obscur: Expedition 33 on Instagram: 'You are a shining example of French audacity and creativity' News By Andy Chalk published 1 May 2025 ...